Grifols (GRFS) Operating Margin (2010 - 2020)
Grifols' (GRFS) quarterly Operating Margin came in at 70.34% in Q1 2020, down 98.0% YoY from 3516.86% in Q2 2019, and little changed on a QoQ basis from 70.36% in Q4 2019.
Grifols (GRFS) Operating Margin (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Operating Margin data on file, last reported at 70.34% in Q1 2020.
- Quarterly Operating Margin fell 98.0% year-over-year to 70.34% in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 48.14% (up 2466.0% YoY) and the FY2025 annual result came in at 16.52%, down 60144.0% from the prior year.
- Operating Margin was little changed at 70.34% in Q1 2020, from 70.36% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 71.32% in Q1 2019 to a low of 6.77% in Q4 2018.
- A 5-year average of 33.42% and a median of 23.95% in 2016 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2016 — Operating Margin slumped 4436 bps — and 2019, when it surged 6358 bps.
- Tracing GRFS's Operating Margin over 5 years: stood at 23.2% in 2016, then gained by 6 bps to 24.69% in 2017, then tumbled by 73 bps to 6.77% in 2018, then jumped by 939 bps to 70.36% in 2019, then dropped by 0 bps to 70.34% in 2020.
- The last three Operating Margin figures came in at 70.34% (Q1 2020), 70.36% (Q4 2019), and 71.32% (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.21 Bn | 633.45 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 468.90 Bn | 462.33 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 378.18 Bn | 371.04 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 302.34 Bn | 294.65 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 182.58 Bn | 179.41 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 161.17 Bn | 149.47 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.37 Bn | 101.20 Bn | 8.24 Bn | 5.72% |
| 10 | Grifols | 5.51 Bn | 4.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 70.34% |
| Dec 31, 2019 | 70.36% |
| Mar 31, 2019 | 71.32% |
| Dec 31, 2018 | 6.77% |
| Jun 30, 2018 | 23.85% |
| Mar 31, 2018 | 23.91% |
| Dec 31, 2017 | 24.69% |
| Jun 30, 2017 | 25.22% |
| Mar 31, 2017 | 23.80% |
| Dec 31, 2016 | 23.20% |
| Sep 30, 2016 | 23.95% |
| Jun 30, 2016 | 22.94% |
| Mar 31, 2016 | 24.14% |
| Dec 31, 2015 | 67.56% |
| Sep 30, 2015 | 25.47% |
| Jun 30, 2015 | 23.62% |
| Mar 31, 2015 | 26.02% |
| Dec 31, 2014 | 25.56% |
| Sep 30, 2014 | 25.85% |
| Jun 30, 2014 | 50.28% |